CELU (Celularity) NonCurrent Deferred Liabilities: $2.81 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELU Celularity Inc CELU
31 GF Score
Price $0.76
GF Value $2.31
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Celularity NonCurrent Deferred Liabilities?

Celularity CELU +1.59% 31 NonCurrent Deferred Liabilities is $2.81 Mil as of Dec. 2025. GuruFocus rates CELU with a GF Score™ of 31/100 and a GF Value™ of $2.31 (Possible Value Trap). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Celularity's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $2.81 Mil.

Celularity NonCurrent Deferred Liabilities Related Terms

Celularity NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Celularity's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celularity NonCurrent Deferred Liabilities Chart

Celularity Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 1.88 2.23 3.20 2.73 2.81

Celularity Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 2.81 2.88 2.77 2.81
CELU
31GF Score
Celularity Inc CELU
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $2.81 Mil mean?
Celularity (CELU) has a NonCurrent Deferred Liabilities of $2.81 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Celularity and its competitors.
Is Celularity's NonCurrent Deferred Liabilities too high?
Celularity's current NonCurrent Deferred Liabilities is $2.81 Mil. Overall, Celularity has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celularity's NonCurrent Deferred Liabilities compare to GRTX and BCDA?
Celularity's NonCurrent Deferred Liabilities of $2.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Celularity and its competitors. Celularity's current NonCurrent Deferred Liabilities is $2.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celularity stock overvalued right now?
Based on GuruFocus' analysis, Celularity (CELU) is currently considered Possible Value Trap. The stock's GF Value™ is $2.31, compared to a current price of $0.76 — trading 67.3% below its estimated fair value. The current NonCurrent Deferred Liabilities is $2.81 Mil. Celularity's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Celularity (CELU), the current NonCurrent Deferred Liabilities is $2.81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celularity (CELU) Overvalued in 2026?

Based on GuruFocus' analysis, Celularity stock appears to be undervalued. The current stock price of $0.76 is trading 67.3% below its estimated GF Value™ of $2.31. GuruFocus considers Celularity to be Possible Value Trap.

Key valuation signals for CELU:

  • NonCurrent Deferred Liabilities: $2.81 Mil
  • GF Value™: $2.31 vs. price of $0.76 (67.3% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celularity Business Description

Address 170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
31GF Score

Get the complete analysis for CELU

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$2.31
GF Value